furazolidone has been researched along with Cancer of Lung in 2 studies
Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, JG | 1 |
| Ji, CH | 1 |
| Shi, MH | 1 |
| Darooee, M | 1 |
| Akbari, V | 1 |
| Taheri, A | 1 |
2 other studies available for furazolidone and Cancer of Lung
| Article | Year |
|---|---|
The anti-infection drug furazolidone inhibits NF-κB signaling and induces cell apoptosis in small cell lung cancer.
Topics: Anti-Infective Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Furazolidone; | 2020 |
Inhibition of aldehyde dehydrogenase by furazolidone nanoemulsion to decrease cisplatin resistance in lung cancer cells.
Topics: A549 Cells; Aldehyde Dehydrogenase; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Furazoli | 2021 |